It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
High-quality, customizable ex vivo assays that reveal molecular and cellular insights helping you make confident decisions through expert guidance, advanced platforms and seamless in vivo integration.
Our ex vivo platforms support your in vivo studies with robust, customizable assays including flow cytometry, qPCR and Western blotting, tailored to your sample analysis needs. We deliver high-quality, reproducible data that advanced your research with precision and reliability.
ex vivo analysis plays a vital role in preclinical studies, enabling precise measurement of biological endpoints. By quantifying biomarkers at the gene and protein level, these assays help validate therapeutic targets, offer insights into your drug’s mechanism of action, and build PK/PD/efficacy relationships. This data supports the translation of your preclinical program into the clinic.
Our Capabilities
ex vivo Analysis Expertise
We combine deep scientific expertise with integrated technologies to deliver translational insights that drive confident, data-informed decision. Our platforms support gene and protein-level analysis, helping you understand molecular responses to disease or treatment.
Gene expression analysis quantifies the transcriptional activity of specific genes or global transcriptomes in tissues or cells, providing insight into molecular responses to disease or treatment.
DNA/RNA Isolation and QC
Gene Expression Analysis (qPCR)
RNAseq
Protein analysis encompasses the detection, quantification, and characterization of proteins to assess expression levels, modifications, and functional status.
Automated Western Blotting (Jess ProteinSimple Analyzer)
High quality histology and IHC capabilities complementing our extensive in vivo platform
Tissue Processing
Morphological Analysis
Makers of Inflammation
Markers of Disease Progression e.g., Fibrosis
A range of biochemical assays are employed to evaluate disease-related changes across different organs, enabling quantitative assessment of key biomarkers, signalling pathways, and metabolic alterations that reflect target engagement and pathological progression.
Comprehensive ex vivo Analytical Support for Your in vivo Study
Immune cell characterization Profile immune cell populations to understand immune responses and modulation.
Immune activation and cytokine assays Measure cell activation and cytokine expression to assess compound activity.
Efficacy and target engagement Link exposure to effect through quantitative molecular and cellular readouts.
Pharmacodynamic analysis Evaluate treatment effects and target engagement in both diseased and healthy tissues.
Cytokine and chemokine profiling Analyze plasma or serum to identify biomarkers of immune and inflammatory activity.
Biochemical assays Quantify enzymes and biomarkers using plate-based and COBAS platforms.
Pharmacokinetic analysis Measure antibody or small molecule levels to support exposure-response assessments.
Gene expression analysis Assess gene or transcriptomic changes to reveal molecular mechanisms.
Biomarker detection Detect and correlate circulating biomarkers with tissue-level effects.
High-content imaging Visualize cellular and tissue phenotypes using multiparametric imaging.
Why Choose Sygnature Discovery for ex vivo Tissue Analysis?
We know that successful preclinical studies start with thoughtful design and dependable analytical support. Our ex vivo platforms are built to deliver reproducible, high-quality data across a wide range of endpoints from immune profiling and gene expression to protein quantification and histological analysis. With bespoke assay development, expert guidance, and advance technologies, we help you make informed decisions at every stage.
Key Benefits
Broad Biomarker Expertise
Full capabilities across pharmacodynamic, predictive and translational endpoints.
Cross-Species Deficiency
Extensive experience with mouse and rat models across therapeutic areas.
Molecular Insight
Gene expression and transcriptomic profiling to assess molecular responses across tissues.
Advanced Analytical Platforms
Expertise in Jess TM, Luminex®, and optimized flow cytometry panels.
Reproducible, High-Quality Data
Skilled scientists delivering consistent, high-quality analysis for in vivo endpoints.
Integrated Discovery Support
Seamless connection between ex vivo analysis and in vivo pharmacology for deeper translational understanding.
Acute Kidney Injury (AKI) poses significant clinical challenges due to its rapid onset and high…
Posters
Related Capabilities
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Integrated solid form and formulation strategies reduce risk, improve stability and solubility, and accelerate progression from candidate selection to clinic.
